Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer.

Oncotarget - 22 Nov 2016

Li Bin, Yao Zhouhong, Wan Yunyan, Lin Dianjie

Abstract excerpt

Epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors (TKIs) have emerged as first-line drugs for non-small cell lung cancers (NSCLCs). However, the resistance to TKIs represents the key limitation for their therapeutic efficacy. We found that the difference of OCT4 expression between NSCLC and the adjacent non-tumourous tissues was statistically significant. Knockdown of OCT4 in NSCLC cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm
Share to Gefitinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Octamer Transcription Factor-3

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to RNA Interference

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 27816965
DOI: 10.18632/oncotarget.12999
PMCID: PMC5363589

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer.PMID 27816965Read ↗

Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.Semantic proximity Read ↗

SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer.Semantic proximity Read ↗

EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

mTOR up-regulation of BEX4 promotes lung adenocarcinoma cell proliferation by potentiating OCT4Semantic proximity Read ↗

OCT4 expression in human non-small cell lung cancer: implications for therapeutic intervention,,Semantic proximity Read ↗

Methylation-modulated PFTK1 regulates gefitinib resistance via Wnt/β-catenin signaling in EGFR mutant non-small-cell lung cancer cells.Semantic proximity Read ↗

Oct4 promoted proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) in colon cancer cells by activating the SCF/c-Kit signaling pathwaySemantic proximity Read ↗

Abnormal expression of FLOT1 correlates with tumor progression and poor survival in patients with non-small cell lung cancerSemantic proximity Read ↗

STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.Semantic proximity Read ↗

Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancerSemantic proximity Read ↗

Gefitinib promotes CXCR4-dependent epithelial to mesenchymal transition via TGF-β1 signaling pathway in lung cancer cells harboring EGFR mutation.Semantic proximity Read ↗

MiR‐133a‐3p attenuates resistance of non‐small cell lung cancer cells to gefitinib by targeting SPAG5Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.